Manni Mohyuddin
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
Manni Mohyuddin
Jul 29, 2024, 07:38 |
Blog
Manni Mohyuddin: My personal preference on T cell redirecting therapy for triple class refractory off trial
Manni Mohyuddin shared a post on X: "In absence of head to head data, my…
Jul 28, 2024, 23:54 |
Blog
Manni Mohyuddin: Long term follow up of elranatamab Phase 2 trial
Manni Mohyuddin posted on X about recent paper by Michael H. Tomasson et al., titled…
Jul 25, 2024, 00:44 |
Opinion
Manni Mohyuddin: The results of the GEM-CESAR trial are a stunning verdict against early intervention in SMM
Manni Mohyuddin shared on X: "The GEM-CESAR trial of a super aggressive approach to SMM…
Jul 10, 2024, 12:35 |
Opinion
Manni Mohyuddin reflects on the analysis of SLiM MM versus traditional CRAB MM
Manni Mohyuddin shared on X: “Finally an analysis of SLiM MM versus traditional CRAB MM.…
Jul 7, 2024, 17:38 |
Blog
Some myeloma updates by Manni Mohyuddin
Manni Mohyuddin shared on X: “Thanks again to Medscape for the opportunity to write about…
Jul 4, 2024, 14:21 |
Insight
A critical appraisal of the long-term follow-up of CASSIOPEIA trial by Manni Mohyuddin
Manni Mohyuddin shared a post on X: "A critical appraisal of the long-term follow-up of…
Jun 24, 2024, 07:13 |
Blog
Manni Mohyuddin: This is a testament to the fact that trainees appreciate critical appraisal
Manni Mohyuddin shared a post by Raj Chakraborty, Assistant Professor of Medicine at Columbia University…
Jun 21, 2024, 14:07 |
Insight
Manni Mohyuddin: Our paper on performance of myeloma staging systems
Manni Mohyuddin shared on X/Twitter: "Our paper on performance of myeloma staging systems just out: Thanks…
Jun 12, 2024, 05:15 |
Blog
Brand new episode on updates in Myeloma MRD - Blood Cancer Talks
Ben Derman, Assistant Professor at the University of Chicago, recently shared a post by Blood…
Jun 7, 2024, 14:45 |
Blog
Manni Mohyuddin on DREAMM-7
Manni Mohyuddin shared on X/Twitter: "In DREAMM-7 (bela/bort/dex vs dara/bort/dex). Only 34% of pts len refractory.…
Jun 5, 2024, 11:41 |
Blog
Manni Mohyuddin: Suggested approach to 1st relapse of myeloma post - ASCO24
Manni Mohyuddin shared on X/Twitter: "Suggested approach to 1st relapse of myeloma post ASCO24 Its suddenly…
May 30, 2024, 11:20 |
Insight
Manni Mohyuddin: The best abstract at ASH 2022 is now fully published
Manni Mohyuddin shared on X: "This was the best abstract at ASH 2022 (IMO). It…
May 29, 2024, 02:38 |
Blog
Manni Mohyuddin: On June 8th, I ride at the Huntsman Cancer Institute sportsfest
Manni Mohyuddin shared on X: "On June 8th, I ride at the Huntsman Cancer Institute…
May 25, 2024, 09:57 |
Societies
Manni Mohyuddin: Six key take-aways regarding the IMROZ trial while we wait for ASCO 24
Manni Mohyuddin shared on X: "The IMROZ trial (Isa-VRd versus VRd for transplant-ineligible myeloma) just…
May 15, 2024, 08:55 |
Insight
Manni Mohyuddin: Philanthropy has allowed us to conduct trials looking at less is more approaches
Manni Mohyuddin shared on X: “I'm participating in the Huntsman SportsFest ride this June. Philanthropy…
May 6, 2024, 08:34 |
Insight
Manni Mohyuddin: Ten important observations about myeloma
Manni Mohyuddin shared a thread on X: . "Ten important observations about myeloma and its…
Apr 29, 2024, 23:03 |
Insight
Manni Mohyuddin: Aaron Goodman and I draw attention to over treatment of multiple myeloma and its precursor states
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University of Utah, recently posted on…
Mar 26, 2024, 09:53 |
Blog
Manni Mohyuddin: Dr. Tefferi's advice is so REFRESHING and AUTHENTIC
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University of Utah, recently posted on…
Mar 17, 2024, 13:43 |
Insight
Samer Al Hadidi: How to counsel patients about Cilta Cel
Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, made the following post on X/Twitter:…
Mar 6, 2024, 08:47 |
Blog
Manni Mohyuddin: Eating plants is good for the world/climate change. But people with cancer are not the right population to be practicing this advocacy on
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University of Utah, recently posted on…
Feb 28, 2024, 18:49 |
Blog
Manni Mohyuddin: Excellent guidelines from the British Society of Hematology
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University of Utah, shared a post…
Feb 26, 2024, 11:02 |
Opinion
Manni Mohyuddin: Cilta-cel is almost as much a 'one and done' treatment as allogeneic transplant is
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Feb 23, 2024, 14:39 |
Insight
Manni Mohyuddin: Why striving for MRD negativity at all costs and having MRD as a primary endpoint may not be ideal
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Feb 22, 2024, 18:58 |
Insight
Manni Mohyuddin: Read this paper carefully, then read it again
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on…
Jan 30, 2024, 15:51 |
Insight
Manni Mohyuddin: It is often well known that the control arm is inferior prior to a single patient being enrolled on trial!
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University of Utah, shared on X/Twitter:…
Jan 26, 2024, 10:47 |
Blog
Manni Mohyuddin: The most important aspect of being an oncologist is communicating effectively
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University of Utah, shared on X:…
Jan 24, 2024, 17:12 |
Blog
Aaron Goodman: Our new prospective study in smoldering myeloma
Aaron Goodman shared a post by Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University…
Jan 17, 2024, 17:28 |
Blog
Manni Mohyuddin: This practice-changing gem of a study has changed my practice already
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University of Utah, shared on X/Twitter:…
Jan 9, 2024, 19:02 |
Blog
Manni Mohyuddin: About the importance of intent to treat analysis
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute, University of Utah, shared a post on…
Jan 6, 2024, 11:43 |
Blog
Manni Mohyuddin: Carfilzomib is NOT better than bortezomib for newly diagnosed myeloma
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on…
Jan 5, 2024, 22:42 |
Opinion
Manni Mohyuddin: How I treat new myeloma
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on…
Jan 5, 2024, 00:05 |
Opinion
Manni Mohyuddin: If a randomized trial fails
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared on…
Dec 31, 2023, 20:04 |
Insight
10 important myeloma publications from 2023 by Manni Mohyuddin
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Dec 31, 2023, 12:01 |
Blog
Manni Mohyuddin: Context matters
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Dec 29, 2023, 16:10 |
Blog
Amalia Aleck: 'Someone has been giving our smoldering MM patients MDS and AML! Let’s GOOOOOOOO!'
Amalia Aleck, Anesthesiologist at Valley Anesthesiology Consultants, tweeted on X/Twitter: "Everyone: it’s a good time of…
Dec 27, 2023, 08:59 |
Insight
Jonas Nilsson: Interesting and balanced discussion on a recent safety signal of CAR-T cells in plasma cell disorders
Jonas Nilsson Chair of Melanoma Discovery at The University of Western Australia and Harry Perkins…
Dec 26, 2023, 12:58 |
Insight
Manni Mohyuddin: Bispecifics and CAR-T's in myeloma trials
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Dec 17, 2023, 16:45 |
Opinion
Manni Mohyuddin: Sad to see surrogacy word loosely used in a plenary session
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, recently…
Dec 16, 2023, 17:08 |
Blog
Manni Mohyuddin: How to treat myeloma after ASH23
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Dec 13, 2023, 08:51 |
Blog
Manni Mohyuddin: So proud of Sara Zhukovsky for her excellent work on inclusion criteria in myeloma trials
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Dec 11, 2023, 11:21 |
Opinion
Manni Mohyuddin: Vague enrollment criteria in smoldering myeloma trials opens door to harm/over-interventionalism
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Nov 28, 2023, 23:17 |
Insight
Manni Mohyuddin: Current trials must have observation/surveillance as control arm
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Nov 23, 2023, 15:49 |
Blog
List of top 10 plasma cell dyscrasia ASH23 abstracts by Manni Mohyuddin
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Nov 14, 2023, 04:36 |
Blog
Manni Mohyuddin: We analyze use of terms that minimize toxicity in myeloma trials
Manni Mohyuddin, Assistant Professor, Huntsman Cancer Institute, University of Utah, shared a post on X/Twitter:…
Nov 6, 2023, 17:36 |
Blog
Manni Mohyuddin: Every day in my clinic, there is selection bias in favor of an increase in PFS for CAR T-cell therapy
Manni Mohyuddin, Assistant Professor at the Huntsman Cancer Institute at the University of Utah, shared…
Oct 15, 2023, 18:19 |
Insight
A deep dive into MGUS in the setting of neuropathy with Manni Mohyuddin
Manni Mohyuddin, Assistant Professor in the Division of Hematology/Bone Marrow Transplant at the University of…
Oct 10, 2023, 21:21 |
Opinion
Manni Mohyuddin: Some days you see unjust racial disparities-such as Medicaid pts not covered for CAR-T.
Manni Mohyuddin, Assistant Professor in the Division of Hematology/Bone Marrow Transplant at the University of…
Sep 23, 2023, 00:52 |
Opinion
Karun Neupane: How young is "Young" in Multiple Myeloma?
Karun Neupane, Internal Medicine Resident at Jacobi Medical Center/Albert Einstein College of Medicine, shared a…
Aug 22, 2023, 18:13 |
Blog
,
Opinion
Cannabis use associated with inferior immunotherapy outcomes OR confounding bias?
Discussions among healthcare professionals ignited on Twitter/X over the following post by Ishwaria Subbiah, the…
Aug 7, 2023, 19:44 |
Drugs
This is a preventable tragedy- that we must avoid repeating - Manni Mohyuddin
Daratumumab has been known to be effective in relapsed myeloma for a long time. Yet…
All:
50
Posts:
1 - 100
Making Personal Experience a Political Priority: Insights from EU Commissioner Stella Kyriakides
Zolbetuximab is now approved by the US FDA
Highlights from NFCR’s GSAC24
SIOP Honoured Hansjörg Riehm with the 2024 Lifetime Achievement Award
Margaret Foti has received the 2024 Beacon Award for Women Leaders in Oncology
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube